Abstract 2045
Background
Thymic carcinoma is one of the rare cancers with a poor prognosis if unresectable. There is no standard chemotherapy for thymic carcinoma since there are only single arm trials or small number of retrospective studies. Here, we retrospectively assessed the effectiveness of chemotherapy for thymic carcinoma treated at the National Cancer Center Hospital Japan.
Methods
Eligible patients had unresectable advanced thymic carcinoma and were treated with chemotherapy between January 2006 and March 2019. We assessed the overall survival (OS), progression-free survival (PFS), and the response rate (RR). OS and PFS were assessed from the start of each treatment line, and of chemotherapy regimen, respectively.
Results
The total number of the subject was 79. As a first line chemotherapy, 72 patients were treated with carboplatin and paclitaxel (CbPx), and the others were treated with S-1 (n = 1), docetaxel (n = 1), and investigational drug (n = 2). Median PFS (mPFS) was 6.2 months and OS (mOS) was 38.9 months. Among 53 patients who received 2ndline chemotherapy, 31 patients received S-1, 5 patients received sunitinib, 3 patients received CbPx, with mPFS of 5.7 months, and mOS of 23.4 months. Among 36 patients who received 3rdline chemotherapy, 15 patients received sunitinib and 7 patients received S-1 with mPFS of 3.0 months, and mOS of 14.0 months. RR and mPFS of each regimens were as follows: CbPx (n = 76) 36.8%, 6.2 months, S-1 (n = 44) 25.0%, 4.1 months, and sunitinib (n = 28) 21.4%, 3.4 months.
Conclusions
This is the largest reported single institute retrospective experience of patients with advanced thymic carcinoma. The efficacy of commonly used chemotherapies was confirmed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Y. Goto: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Chugai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho Pharmaceutical; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Glaxo Smith Kline; Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy: Guardant Health ; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol Myers Squibb; Speaker Bureau / Expert testimony: Shionogi Pharma; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Kyorin. S. Kanda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self): BMS; Honoraria (self): Chugai; Honoraria (self): MSD. H. Horinouchi: Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol Myers Squibb; Speaker Bureau / Expert testimony: Kyowa-kirin; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Kyorin; Research grant / Funding (institution): Genomic Health. N. Yamamoto: Research grant / Funding (institution): Astellas; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Taiho; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Novartis; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Kyowa-Hakko Kirin; Advisory / Consultancy, Research grant / Funding (institution): Takeda; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono; Research grant / Funding (institution): Janssen Pharma; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Merck; Advisory / Consultancy: Otsuka; Advisory / Consultancy: Cimic. Y. Ohe: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Ono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bayer; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): MSD; Honoraria (self), Research grant / Funding (institution): Taiho; Advisory / Consultancy, Research grant / Funding (institution): Kyorin; Advisory / Consultancy: Celltrion; Advisory / Consultancy: Amgen; Research grant / Funding (institution): Dainippon Sumitomo; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Kissei; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Janssen. All other authors have declared no conflicts of interest.
Resources from the same session
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract